When the Clock Runs Out: Biologics, Biosimilars, and the Revenue Reckoning Reshaping Biotech

For decades, the patent system served as biotech's most reliable financial instrument. A molecule discovered in a laboratory, shepherded through clinical trials at extraordinary cost, and approved by the FDA could generate protected revenues for twenty years — long enough, in theory, to fund the next generation of discoveries. That model is now colliding with arithmetic it cannot escape. A wave of blockbuster biologics, many of them among the highest-grossing drugs in pharmaceutical history, is approaching the end of its patent-protected life. The consequences will be felt not only in corporate earnings reports but in research laboratories, clinical pipelines, and ultimately, in the availability and affordability of treatments for patients.

The Drugs at the Center of the Storm

The scale of what is at stake becomes clear when individual products are examined. Humira — adalimumab, AbbVie's flagship anti-inflammatory — lost its primary US patent protection in 2023 after generating over $20 billion annually at its peak. Its entry into biosimilar competition marked the opening of a new competitive era, with multiple manufacturers introducing lower-cost alternatives almost simultaneously. The revenue erosion has been swift and significant, though AbbVie anticipated the transition by negotiating licensing deals that delayed the sharpest declines.

Humira, however, is not an isolated case. Keytruda, Merck's pembrolizumab, which has become the backbone of immuno-oncology treatment for dozens of cancer indications, faces patent expirations beginning later this decade. Stelara, Opdivo, Eylea, and Dupixent — each representing billions in annual revenue — are positioned along the same trajectory at varying intervals. Analysts at several investment firms have estimated that the cumulative revenue at risk from biologic patent expirations between 2025 and 2035 could exceed $300 billion globally, with US markets bearing a disproportionate share of that exposure.

How Biosimilars Are Rewriting Competition

Unlike the generic drug market for small-molecule pharmaceuticals, the biosimilar landscape is structurally more complex. Biologics are large, intricate protein molecules manufactured through living cell systems — a process that cannot be replicated with the same precision as synthesizing a simple chemical compound. Demonstrating biosimilarity requires extensive analytical and clinical data, and the regulatory pathway, while more streamlined than it once was, remains demanding.

That complexity has historically suppressed competition. Where a small-molecule drug might attract a dozen generic entrants within months of patent expiration, biosimilar markets often develop more slowly and with fewer players. The capital requirements for biosimilar manufacturing are substantial, and only companies with established biomanufacturing infrastructure can compete effectively. Nevertheless, the market is maturing. The FDA has approved a growing roster of biosimilars across therapeutic categories, and pharmacy benefit managers and hospital systems are increasingly willing to substitute biosimilars for reference products when cost differentials are meaningful.

For originator companies, the response has been a combination of litigation, lifecycle management, and negotiated licensing. Patent thickets — the practice of filing numerous secondary patents covering formulations, delivery devices, and manufacturing processes — have extended effective market exclusivity well beyond primary patent expiration dates. Critics argue that this strategy delays the price competition that biosimilars are designed to introduce, while defenders contend that secondary innovation genuinely warrants protection. The legal and regulatory battles over these practices continue to shape the competitive environment in ways that will determine how quickly patients and payers actually benefit from biosimilar availability.

The Pipeline Problem

The deeper structural challenge is one of timing. Developing a new biologic from early discovery through FDA approval typically requires ten to fifteen years and investments that routinely exceed $1 billion per approved asset, when accounting for the cost of failures. The revenue generated by today's blockbusters is what funds tomorrow's research. When that revenue contracts sharply and simultaneously across multiple products, the financial capacity to sustain ambitious pipelines compresses accordingly.

Several large-cap biotechs and pharmaceutical companies have already announced workforce reductions and pipeline reprioritizations that observers connect, at least in part, to anticipated revenue pressures from patent expirations. The challenge is particularly acute for companies that built their financial identity around a single dominant franchise. Diversification — across therapeutic areas, modalities, and patent timelines — has become a strategic imperative, but executing diversification requires precisely the capital that patent cliffs threaten to erode.

Smaller biotechs face a related but distinct version of this problem. Many operate on the assumption that a validated asset will attract partnership or acquisition interest from larger organizations with the resources to commercialize it. When those larger organizations are themselves managing revenue transitions, their appetite for expensive acquisitions may diminish, tightening the capital flow that sustains early-stage innovation.

Next-Generation Modalities as a Strategic Response

One response to the patent cliff has been an accelerated pivot toward therapeutic modalities that originator companies believe will be harder for biosimilar manufacturers to replicate. Gene therapies, RNA-based medicines, cell therapies, and bispecific antibodies represent categories where manufacturing complexity and scientific novelty may provide more durable competitive differentiation than traditional biologics.

The logic is straightforward: if the core vulnerability of first-generation biologics is their susceptibility to biosimilar competition once patents expire, then developing therapies that are technically harder to copy — or that address conditions with smaller patient populations and therefore less attractive biosimilar economics — could extend the period of protected revenue. Gene therapies, in particular, carry the theoretical advantage of single-administration curative intent, which changes the revenue model entirely from chronic maintenance dosing to a one-time transaction.

Whether this strategic pivot can generate sufficient revenue at scale to replace what legacy biologics have historically provided remains unproven. Gene therapies approved to date carry extraordinarily high list prices, and payer resistance to those prices is growing. The commercial infrastructure required to deliver and reimburse single-administration therapies at scale does not yet exist in a mature form. The transition from a recurring-revenue biologic model to a one-time-payment gene therapy model introduces financial risks that neither manufacturers nor payers have fully resolved.

A Structural Reckoning, Not a Temporary Disruption

What distinguishes the current patent expiration wave from previous cycles is its concentration. Multiple high-revenue assets are losing protection within a compressed timeframe, limiting the industry's ability to absorb losses sequentially. The financial buffers that once allowed companies to manage one patent cliff while growing another franchise are under simultaneous pressure across the sector.

For patients, the outcome is not uniformly negative. Biosimilar competition, when it functions effectively, reduces drug costs and expands access — outcomes that the US healthcare system urgently needs. Humira's biosimilar entrants have already produced meaningful price reductions in institutional settings, even if list price dynamics in the retail pharmacy channel remain complicated by rebate structures.

For the industry, the reckoning is more ambiguous. The patent cliff is not a failure of the system — it is the system working as designed, eventually exposing protected innovations to competitive pricing. The question is whether biotech's research engine, which has produced genuinely transformative medicines over the past three decades, can sustain its output when the financial model that powered it is under such concentrated stress. The answer will be written not in press releases, but in the clinical trial databases, manufacturing facilities, and regulatory submissions of the next ten years.